PD-L1 immunoreactivity and its association with tumor grade in canine mammary carcinomas.

Authors

Gina P Duarte-Isaza, Gina M Mendez-Callejas, Cruz E Enríquez-Valencia, Darwin A Moreno-Pérez, Carolina Gallego López

Published in

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. Pages 10406387261479705. Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Programmed death ligand 1 (PD-L1) is a transmembrane protein involved in tumor immune evasion. Although widely studied in human oncology, its role in canine mammary carcinoma remains poorly characterized. We quantified pd-l1 gene mRNA levels by reverse-transcription quantitative real-time PCR (RT-qPCR), evaluated PD-L1 immunoreactivity by immunohistochemistry (IHC) in canine mammary carcinomas, and tested their association with tumor grade and epidemiologic factors using 96 formalin-fixed, paraffin-embedded tissue samples. The mean age of affected dogs was 9.6 y, with Miniature Poodles and mixed-breed dogs most frequently represented. We found no statistically significant associations between pd-l1 mRNA levels with histologic subtype or epidemiologic factors. However, PD-L1 immunoreactivity was significantly associated with tumor grade in the bivariate analysis (p = 0.017; Cramer V = 0.3), supporting the diagnostic value of PD-L1 IHC in canine mammary carcinomas and suggesting its utility as a marker of tumor aggressiveness.

PMID:
42779502
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.